Aastrom Biosciences has enrolled the first patients in the ixCELL-DCM Phase IIb clinical trial of ixmyelocel-T in the US.
The Phase IIb study will evaluate the efficacy and safety of ixmyelocel-T in treating patients with advanced heart failure due to ischemic dilated cardiomyopathy (ischemic DCM).
Go deeper with GlobalData
Aastrom Biosciences acting chief medical officer Dr David Recker said; "Enrolling the first patients in the ixCELL-DCM trial is an important milestone in our effort to bring this potential new treatment for advanced heart failure to thousands of people who might benefit from it."
The randomised, double-blind, placebo-controlled Phase IIb study is expected to enrol 108 patients at 30 sites in the US.
Ixmyelocel-T will be administered through catheter-based injections to patients with advanced heart failure due to ischemic DCM.
The average number of events per patient, such as all-cause mortality, all-cause hospitalisations or unplanned hospital visits to treat worsening heart failure, will be the primary endpoint.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe study patients will undergo follow up for 12 months.
Aastrom president and chief executive officer Nick Colangelo said the clinical programme is focused on the development of ixmyelocel-T for the treatment of dilated cardiomyopathy and other rare disease indications.
"We have increased the number of sites participating in this study, which will help us build momentum in patient enrolment and complete the trial on schedule," Colangelo said.
